Studies have demonstrated that tumor cells can evade targeted CD19 immunotherapy by the acquisition of frameshift mutations in exons 2 to 5 and point mutations in exon 3 of CD19, altering the levels of the antigen on the cell surfaces and thus evasion of the immune response [114, 130, 131]. The gene discussed is CD19; the disease is neoplasm.